Sinopharm Group Co Ltd banner

Sinopharm Group Co Ltd
F:X2S

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
F:X2S
Watchlist
Price: 1.865 EUR 0.87% Market Closed
Market Cap: €5.8B

Wall St Price Targets

X2S Price Targets Summary
Sinopharm Group Co Ltd

Wall Street analysts forecast X2S stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for X2S is 2.69 EUR with a low forecast of 2.002 EUR and a high forecast of 3.302 EUR.

Lowest Forecast
Price Target
2.002 EUR
7% Upside
Average Forecast
Price Target
2.69 EUR
44% Upside
Highest Forecast
Price Target
3.302 EUR
77% Upside
Sinopharm Group Co Ltd Competitors:
Price Targets
WRLD
World Acceptance Corp
-14% Downside

Revenue
Forecast

13% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
13% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

12% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Sinopharm Group Co Ltd

Operating Income
Forecast

11% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
11% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.

Pre-Tax Income
Forecast

12% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Sinopharm Group Co Ltd

Net Income
Forecast

11% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
11% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 9%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is X2S's stock price target?
Price Target
2.69 EUR

According to Wall Street analysts, the average 1-year price target for X2S is 2.69 EUR with a low forecast of 2.002 EUR and a high forecast of 3.302 EUR.

What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.

What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%

Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.

What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 9%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett